Wells Fargo & Company Cuts Omnicell (NASDAQ:OMCL) Price Target to $38.00

Omnicell (NASDAQ:OMCL) had its price target decreased by Wells Fargo & Company from $40.00 to $38.00 in a research note published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Other equities analysts have also issued reports about the company. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Tuesday, April 15th. Benchmark reiterated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $50.67.

Omnicell Stock Down 2.2 %

Omnicell stock opened at $30.28 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.42 billion, a PE ratio of 112.15, a PEG ratio of 7.53 and a beta of 0.78. The firm’s fifty day moving average is $35.27 and its 200 day moving average is $41.27. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, sell-side analysts predict that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Accurate Wealth Management LLC grew its position in Omnicell by 27.4% during the first quarter. Accurate Wealth Management LLC now owns 36,131 shares of the company’s stock valued at $1,263,000 after buying an additional 7,762 shares during the period. Bridge City Capital LLC boosted its holdings in Omnicell by 1.6% in the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company’s stock worth $1,403,000 after buying an additional 650 shares during the period. GAMMA Investing LLC grew its stake in Omnicell by 2,892.5% in the 1st quarter. GAMMA Investing LLC now owns 43,211 shares of the company’s stock valued at $1,511,000 after buying an additional 41,767 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Omnicell by 22.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company’s stock valued at $5,306,000 after acquiring an additional 21,847 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in shares of Omnicell by 286.4% in the fourth quarter. Squarepoint Ops LLC now owns 149,717 shares of the company’s stock worth $6,665,000 after acquiring an additional 110,966 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.